Achilles Therapeutics plc

NasdaqCM ACHL

Achilles Therapeutics plc Share Price on January 29, 2025: USD 1.13

Achilles Therapeutics plc Share Price is USD 1.13 on January 29, 2025, a 18.93% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Achilles Therapeutics plc 52-week high Share Price is USD 1.57 on February 28, 2024, which is 38.94% above the current Share Price.
Achilles Therapeutics plc 52-week low Share Price is USD 0.70 on September 11, 2024, which is -38.04% below the current Share Price.
Achilles Therapeutics plc average Share Price for the last 52 weeks is USD 0.96.

Key data

Date	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)

NasdaqCM: ACHL

Achilles Therapeutics plc

CEO	Dr. Iraj Ali Ph.D.
IPO Date	March 31, 2021
Location	United Kingdom
Headquarters	245 Hammersmith Road
Employees	204
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

Key trends

Past 5 years